SCHEMBL4168167

SCHEMBL4168167

CC1COCC(C)N1c1cc(C2(S(=O)(=O)c3ccccc3)CC2)nc(-c2ccc(N)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ATR Q13535 18/20 0.47
PIK3CA P42336 4/20 0.39
MTOR P42345 4/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
ATRIP Q8WXE1 3/20 0.39
TAF1 P21675 3/20 0.39
KCNH2 Q12809 2/20 0.39
PIK3R1 P27986 2/20 0.39
PRKDC P78527 2/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207774 1.00 ATR (0.47) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4207176 0.88 ATR (0.52) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4198487 0.87 ATR (0.54) ATRPIK3CAMTORATRIPTAF1
SCHEMBL4206721 0.85 ATR (0.53) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4210192 0.85 ATR (0.49) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4196995 0.85 ATR (0.49) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4205311 0.85 MTOR (0.53) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL4167867 0.85 MTOR (0.53) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL3928752 0.84 PIK3CA (0.45) ATRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL8098740 0.83 MTOR (0.53) ATRPIK3CAMTORPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074118-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES AstraZeneca AB (SE) 2009-07-01 EP disclosed
WO-2009007748-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 WO disclosed